Pharma BD Deal Intelligence

Sanofi S.A. / Seawolf Therapeutics

2026 · Licensing/Option · $1.2B · Complete

Seawolf Therapeutics emerged from stealth with a $100 million Series A and simultaneously disclosed a multi-target DNA medicines research collaboration and exclusive license agreement with Sanofi. Seawolf is eligible for up to $1.2 billion across milestone payments plus tiered royalties on resulting products. The collaboration applies Seawolf's TRIDENT platform (Targeted RNA-Induced DNA Expression via Nuclear Translocation), which pairs a proprietary lipid nanoparticle with an immune-quiet DNA payload encoding a therapeutic transgene plus an auxiliary factor that facilitates nuclear access. Unlike viral DNA-delivery approaches, TRIDENT therapies are designed to be redosable. Named targets cover undisclosed therapies for bleeding disorders plus additional unnamed indications. The Series A was led by Versant, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →